Today: 12 November 2025
Subscribe
Browse Category

NASDAQ:VKTX News 26 September 2025 - 11 November 2025

Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking Therapeutics (VKTX) on Nov. 11, 2025: Stifel Fireside Chat Today, Fresh VK2735 Obesity Data From ObesityWeek, and Phase 3 VANQUISH Progress

Published: November 11, 2025 Viking Therapeutics, Inc. (NASDAQ: VKTX) steps into the spotlight today with a scheduled fireside chat at the Stifel 2025 Healthcare Conference in New York (4:40–5:10 p.m. ET). The appearance comes on the heels of new clinical analyses from ObesityWeek® 2025 and an October corporate update outlining steady Phase 3 progress for its lead obesity candidate, VK2735. Viking Therapeutics InvestorRoom What’s happening today (Nov. 11) Viking’s management will host a fireside chat and hold 1×1 investor meetings at Stifel’s conference, part of a busy November investor-relations calendar that also includes a corporate presentation at the Jefferies 2025
11 November 2025
 ·  ·  ·  ·  · 
Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead

Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead

Market snapshot Last close (Fri, Nov 7): $36.77.Intraday range: $34.69 – $37.50; volume: ~4.65M. Why VKTX is back on watch this week 1) Fresh institutional interest and ownership trends Ethos Financial Group’s new position adds to a year when institutions already control roughly three‑quarters of the float. MarketBeat’s automated brief also captures the latest insider activity (including October sales by the CEO and a director), and a blended “Moderate Buy” Street view. While 13F adds don’t guarantee direction, they often increase visibility ahead of catalysts. MarketBeat 2) Technical picture: mixed near‑term, firmer mid‑term Today’s quant readout pegs $35–$38 as the
9 November 2025
 ·  ·  ·  ·  · 
Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

What to Know Before Markets Open on October 20, 2025 VKTX Stock Steadies After Volatile Stretch Viking’s stock has stabilized in recent sessions, trading in the mid-$30s after a roller-coaster few months. It ended Friday at $33.53 marketbeat.com, roughly flat on the week and not far from its intraday high of ~$36.80 on Thursday ir.vikingtherapeutics.com. This marks a dramatic recovery from mid-August, when VKTX plunged over 40% in one day following a crucial trial announcement ts2.tech. Back then, Viking had unveiled results from a Phase 2 study of its oral obesity pill that missed investor expectations, triggering a sharp selloff.
19 October 2025
 ·  ·  ·  ·  · 
Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

Key facts (today) The U.S. stock market today — what moved prices 1) The data that mattered: PCE & spendingMarkets exhaled as the Fed’s preferred inflation gauge arrived exactly as expected: headline PCE +0.3% m/m (2.7% y/y), core +0.2% m/m (2.9% y/y). Treasury yields drifted lower, with the 10‑yr near 4.18% and the 2‑yr around 3.65%, signaling relief that there was no upside shock. Futures ticked higher on the print.  Reuters “This should give some reassurances on the inflation side,” said Doug Beath of Wells Fargo Investment Institute.  Reuters Consumer spending stayed solid in August, adding to this week’s Q2 GDP revision to 3.8%. The resilience complicates the Fed’s job (growth strong, inflation easing
26 September 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Go toTop